Brief: Gyre Therapeutics Enters Into Agreement To Acquire Cullgen To Gain Targeted Protein Degradation Platform And Pipeline
02/03/2026 13:29
March 2 (Reuters) - Gyre Therapeutics Inc GYRE.O: GYRE THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE CULLGEN TO GAIN TARGETED PROTEIN DEGRADATION PLATFORM AND PIPELINE GYRE THERAPEUTICS INC: ALL-STOCK TRANSACTION VALUED AT APPROXIMATELY $300 MILLION GYRE THERAPEUTICS INC - DEAL VALUED AT ABOUT $300 MILLION GYRE THERAPEUTICS INC - PING ZHANG TO REMAIN AS EXECUTIVE CHAIRMAN Source text: ID:nGNX160j31 Further company coverage: GYRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes